One-Shot radiation may tame returning prostate cancer
NCT ID NCT07635108
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a single, powerful dose of MRI-guided radiation can safely treat prostate cancer that has come back in a few lymph nodes after initial treatment. Forty-eight men will receive one 24 Gy radiation session aimed precisely at the affected nodes. The main goal is to check for severe side effects, while also seeing if the treatment controls the cancer and delays the need for hormone therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
radiation therapy (single high-dose MR-guided stereotactic body radiotherapy)
What this could lead to
If successful, this could offer a way to control prostate cancer that has returned in a few lymph nodes, potentially delaying the need for hormone therapy and its side effects.
What could go wrong
This is a small, early-phase trial with only 48 participants, so results may not apply to everyone. The treatment involves high-dose radiation, which carries risks of severe side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Oncology, Odense University Hospital
Odense, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••